Table 2 Comparison of clinical features between juvenile-onset and adult-onset OMG patients
Variables | < 20 y | ≥ 20 y | P value |
|---|---|---|---|
Gender (Male/Female) | 110 (53/57) | 113 (63/50) | 0.258 |
Initial symptoms | |||
Unilateral ptosis | 58/110 (52.7%) | 52/113 (46.0%) | 0.316 |
Bilateral ptosis | 20/110 (18.2%) | 20/113 (17.7%) | 0.925 |
Diplopia | 2/110 (1.8%) | 8/113 (7.1%) | 0.102 |
Unilateral ptosis with diplopia | 18/110 (16.4%) | 24/113 (21.2%) | 0.352 |
Bilateral ptosis with diplopia | 12/110 (10.9%) | 9/113 (8.0%) | 0.452 |
Neostigmine test (+) | 74/78 (94.9%) | 89/93 (95.7%) | 0.799 |
Positive rate of RNS test | |||
Facial nerve | 10/23 (43.5%) | 15/61 (24.6%) | 0.091 |
Axillary nerve | 2/24 (8.3%) | 16/52 (30.8%) | 0.032 |
Ulnar nerve | 0/31 | 2/44 (4.5%) | – |
Thyroid abnormality | 5/42 (11.9%) | 12/60 (20.0%) | 0.280 |
Hyperthyroidism | 2/5 (40%) | 7/12 (58.3%) | 0.620 |
Subclinical hyperthyroidism | 2/5 (40%) | 2/12 (16.7%) | 0.538 |
Hypothyroidism | 1/5 (20%) | 1/12 (8.3%) | 0.515 |
Subclinical hypothyroidism | 0/5 | 2/12 (16.7%) | – |
Thymus abnormality | 12/76 (15.8%) | 27/98 (27.6%) | 0.065 |
Thymoma | 7/12 (58.3%) | 18/27 (66.7%) | 0.723 |
Thymic hyperplasia | 3/12 (25.0%) | 4/27 (14.8%) | 0.654 |
Non-degraded thymus | 2/12 (16.7%) | 5/27 (18.5%) | 1.000 |